Working… Menu
Trial record 1 of 1 for:    A Phase II Study of Cabozantinib (XL184) Plus Pembrolizumab For Recurrent, Persistent and/or Metastatic Cervical Cancer
Previous Study | Return to List | Next Study

Cabozantinib Plus Pembrolizumab for Recurrent, Persistent and/or Metastatic Cervical Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT04230954
Recruitment Status : Recruiting
First Posted : January 18, 2020
Last Update Posted : August 20, 2020
Information provided by (Responsible Party):
University of South Alabama

No Study Results Posted on for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : June 28, 2021
Estimated Study Completion Date : January 28, 2022